The contaminated drug that caused last fall’s fungal meningitis outbreak and killed 55 people is just the tip of the iceberg of an industry-wide problem, according to a new report released today by ConnPIRG. The meningitis outbreak was simply the latest and deadliest in a long line of errors and risky practices by compounding pharmacies.
“Consumers should always be confident that their drugs are safe and effective, regardless of whether their drugs are manufactured at a compounding facility or a pharmaceutical company. Our prescription drugs should not lead to the illness and death of our loved ones,” said Abe Scarr, advocate for ConnPIRG.
Traditionally, compounding pharmacies have engaged in the practice of customizing a medication for a particular patient – such as altering the dosage or turning a pill into a liquid for patients who have difficulty swallowing. But now, large compounding pharmacies are behaving exactly like drug manufacturers. Although they manufacture drugs in bulk, large compounding pharmacies do not conduct rigorous testing, nor do they adhere to safe manufacturing processes that pharmaceutical companies are required to implement. Instead they are exploiting legal loopholes in the law to escape the necessary safety standards and oversight.
The report, “Prescription for Danger,” analyzed more than 40 warning letters issued by the Food and Drug Administration (FDA) to compounding pharmacies from January 2002 to December 2012. Each firm was cited for multiple violations of the Food, Drug, and Cosmetic Act, such as making new drugs that have not been tested for safety and effectiveness, and making drugs in unsanitary conditions.
“As the PIRG report accurately points out, this ‘shadow industry’ of compounding pharmacies recklessly puts Americans’ lives at risk by ignoring basic standards for safety and cleanliness when performing large-scale compounding operations,” Senator Richard Blumenthal said. “I hope the FDA will assert its full authority over large-scale compounders to protect the public from unsafe and untested drug products. These pharmacies currently exist in a legal netherworld – outside the bounds of state and federal oversight – and need to be heavily regulated by the agency.”
“Congress and the FDA need to ensure that drugs made in compounding pharmacies are safe,” said Scarr. “We must never repeat the avoidable tragedy of having contaminated and unsafe drugs on the market again.”
The report highlights some of the most blatant violations by compounding pharmacies, including:
- In 2007 FDA inspectors found that ComputeRx/Broncho-Dose, in Connecticut was not operating like a retail pharmacy, but more like a large pharmaceutical manufacturer. They were mass producing an asthma drug, in various strengths and formulations that were not “medically therapeutic.” The drugs were misbranded and labeled at a stronger dosage then they actually were. The pharmacy was also not following sterile manufacturing practices to
- In 2002, consumers complained about arthritis pain relief injections produced by Lee Pharmacy in Fort Smith, Arkansas. The FDA analyzed the injections and found they were contaminated with penicilliium rugulosum, a potentially lethal fungus.
- In 2009, Hopewell Pharmacy in Hopewell, New Jersey, was found to be using a solvent called diethylene glycol monoethyl ether in sterile injections used for the treatment of varicose veins. This ingredient is normally used in industrial cleaners and is not approved by the FDA for use in drug manufacturing.
- In 2005, University Pharmacy in Salt Lake City, Utah, was investigated because a 25-year-old woman lapsed into a coma and died from using Photocaine, a topical anesthetic cream produced by the pharmacy without the approval of the FDA.
The report is available at http://www.connpirg.org/reports/ctp/prescription-danger
ConnPIRG, the Connecticut Public Interest Research Group, is a nonprofit, nonpartisan public interest advocacy organization that takes on powerful interests on behalf of its members, working to win concrete results for our health and well-being. www.connpirg.org
- Connecticut Officials Investigating New Jersey-based “Med Prep” Compounding Pharmacy
- Feds Take Steps To Ease Cancer Drug Shortages
- Connecticut Doctor-Dispensed Drug Prices Still Higher Than Pharmacies, Study Finds
- Massachusetts Firm Eyed As Culprit In Steroid That Has Killed Seven Affected 91 In Fungal Meningitis
- McKesson Corp To Pay Connecticut $15 Million Fine For Artificially Boosting Drug Charges
- GlaxoSmithKline Agrees To Pay $750 million To Settle Criminal And Civil Complaints